Insider Trading disclosures for Niagen Bioscience Inc.

The latest disclosure was made by Carlos Luis Lopez in Niagen Bioscience Inc. where a trade of 273 Common Stock done at an average price of $7.9 was reported to US exchanges on March 7, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Show

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Carlos Luis Lopez	SVP, General Counsel	Purchase of securities on an exchange or from another person at price $ 7.86 per share.	07 Mar 2025	273	2,251 (0%)	0%	7.9	2,146	Common Stock
Robert N. Fried	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	25 Feb 2025	1,518,600	1,518,600	-		-	Performance Stock Unit
Robert N. Fried	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Feb 2025	492,278	492,278	-		-	Employee Stock Options (right to buy)
Ozan Pamir	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Feb 2025	17,230	17,230	-		-	Employee Stock Options (right to buy)
Carlos Luis Lopez	SVP, General Counsel	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Feb 2025	19,691	19,691	-		-	Employee Stock Options (right to buy)
Frank L. Jaksch	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.66 per share.	13 Dec 2024	50,001	281,340 (0%)	0%	3.7	183,004	Common Stock
Jaksch Frank L.	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	13 Dec 2024	50,001	0	-		-	Employee Stock Options (right to buy)
Frank L. Jaksch	Director	Sale of securities on an exchange or to another person at price $ 6.19 per share.	13 Dec 2024	37,161	244,179 (0%)	0%	6.2	229,956	Common Stock
Ozan Pamir	Chief Financial Officer	Purchase of securities on an exchange or from another person at price $ 7.36 per share.	22 Nov 2024	2,907	2,907 (0%)	0%	7.4	21,397	Common Stock
Ozan Pamir	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	21 Oct 2024	146,544	146,544	-		-	Employee Stock Options (right to buy)
Kristin Patrick	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.64 per share.	23 Aug 2024	3,000	3,000 (0%)	0%	1.6	4,920	Common Stock
Kristin Patrick	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	23 Aug 2024	20,000	0	-		-	Stock Option (right to buy)
Kristin Patrick	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	23 Aug 2024	3,000	17,000	-		-	Stock Option (right to buy)
Kristin Patrick	Director	Sale of securities on an exchange or to another person at price $ 3.57 per share.	23 Aug 2024	23,000	0 (0%)	0%	3.6	82,110	Common Stock
Kristin Patrick	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.67 per share.	23 Aug 2024	20,000	23,000 (0%)	0%	1.7	33,400	Common Stock
Frank L. Jaksch	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	20 Jun 2024	20,000	20,000	-		-	Stock Option (right to buy)
Ann Cohen	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	20 Jun 2024	20,000	20,000	-		-	Stock Option (right to buy)
Steven D. Rubin	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	20 Jun 2024	20,000	20,000	-		-	Stock Option (right to buy)
Hamed Shahbazi	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	20 Jun 2024	20,000	20,000	-		-	Stock Option (right to buy)
Wendy Yu	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	20 Jun 2024	20,000	20,000	-		-	Stock Option (right to buy)
Kristin Patrick	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	20 Jun 2024	20,000	20,000	-		-	Stock Option (right to buy)
Gary Ng	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	20 Jun 2024	20,000	20,000	-		-	Stock Option (right to buy)
Brianna Gerber	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 Feb 2024	213,886	213,886	-		-	Employee Stock Options (right to buy)
Robert Fried N.	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 Feb 2024	399,568	399,568	-		-	Employee Stock Options (right to buy)
Brianna Gerber	Chief Financial Officer	Purchase of securities on an exchange or from another person at price $ 1.41 per share.	01 Dec 2023	5,000	27,436 (0%)	0%	1.4	7,050	Common Stock
Brianna Gerber	Chief Financial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2023	22,436	44,872	-		-	Restricted Stock Unit
Brianna Gerber	Chief Financial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Aug 2023	22,436	22,436 (0%)	0%		-	Common Stock
Steven D. Rubin	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jun 2023	20,000	20,000	-		-	Stock Option (right to buy)
Frank L. Jaksch	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jun 2023	20,000	20,000	-		-	Stock Option (right to buy)
Hamed Shahbazi	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jun 2023	20,000	20,000	-		-	Stock Option (right to buy)
Wendy Yu	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jun 2023	20,000	20,000	-		-	Stock Option (right to buy)
Kristin Patrick	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jun 2023	20,000	20,000	-		-	Stock Option (right to buy)
Gary Ng	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jun 2023	20,000	20,000	-		-	Stock Option (right to buy)
Ann Cohen	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jun 2023	20,000	20,000	-		-	Stock Option (right to buy)
Frank L. Jaksch	Director	Purchase of securities on an exchange or from another person at price $ 1.69 per share.	12 Jun 2023	7,000	231,339 (0%)	0%	1.7	11,830	Common Stock
Robert N. Fried	Director, Chief Executive Officer	Purchase of securities on an exchange or from another person at price $ 1.42 per share.	31 May 2023	7,000	95,001 (0%)	0%	1.4	9,940	Common Stock
Steven D. Rubin	Director	Purchase of securities on an exchange or from another person at price $ 1.46 per share.	25 May 2023	7,000	7,000 (0%)	0%	1.5	10,220	Common Stock
Robert N. Fried	Director, Cheif Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Feb 2023	306,366	306,366	-		-	Employee Stock Options (right to buy)
Brianna Gerber	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Feb 2023	163,996	163,996	-		-	Employee Stock Options (right to buy)
Robert N. Fried	Director, Cheif Executive Officer	Purchase of securities on an exchange or from another person at price $ 1.25 per share.	30 Sep 2022	80,000	972,314 (1%)	0%	1.3	100,000	Common Stock
Kevin M. Farr	CHIEF FINANCIAL OFFICER	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2022	89,189	89,189	-		-	Restricted Stock Unit
Brianna Gerber	SVP Finance / Interim CFO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2022	67,308	67,308	-		-	Restricted Stock Unit
Brianna Gerber	SVP Finance / Interim CFO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Aug 2022	100,460	100,460	-		-	Employee Stock Options (right to buy)
Hamed Shahbazi	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Aug 2022	40,000	40,000	-		-	Stock Option (right to buy)
Steven D. Rubin	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	16 Jun 2022	20,000	20,000	-		-	Stock Option (right to buy)
Wendy Yu	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	16 Jun 2022	20,000	20,000	-		-	Stock Option (right to buy)
Kristin Patrick	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	16 Jun 2022	20,000	20,000	-		-	Stock Option (right to buy)
Gary Ng	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	16 Jun 2022	20,000	20,000	-		-	Stock Option (right to buy)
Ann Cohen	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	16 Jun 2022	20,000	20,000	-		-	Stock Option (right to buy)
Kristin Patrick	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Apr 2022	40,000	40,000	-		-	Stock Option (right to buy)

Showing 1 to 50 of 278 entries

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

236.96% Gain from 52W Low

Insider Trading disclosures for Niagen Bioscience Inc.

The latest disclosure was made by Carlos Luis Lopez in Niagen Bioscience Inc. where a trade of 273 Common Stock done at an average price of $7.9 was reported to US exchanges on March 7, 2025.

Screeners based on Insider Trading and SAST parameters